

Reference number(s)

1583-H

Initial Quantity Limit Albendazole, Biltricide, Egaten, Emverm

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
albendazole (brand unavailable)	albendazole
Biltricide	praziquante
Egaten	triclabendazole
Emverm	mebendazole

Indications

Albendazole

FDA-Approved Indications

Neurocysticercosis

Albenza tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Hydatid Disease

Albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Biltricide

FDA-Approved Indications

Biltricide is indicated in patients aged 1 year and older for the treatment of the following infections:

Albendazole, Biltricide, Egaten, Emverm Limit 1583-H P03-2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

- Schistosomiasis due to all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and
- Clonorchiasis and Opisthorchiasis due to the liver flukes, Clonorchis sinensis/Opisthorchis
 viverrini (approval of this indication was based on studies in which the two species were not
 differentiated).

Compendial Uses

Treatment of intestinal infections caused by Taenia solium, Taenia saginata, Diphyllobothrium latum and Hymenolepis nana.^{5,6}

Egaten

FDA-Approved Indications

Egaten is indicated for the treatment of fascioliasis in patients 6 years of age and older.

Emverm

FDA-Approved Indications

Emverm is indicated for the treatment of patients two years of age and older with gastrointestinal infections caused by Ancylostoma duodenale (hookworm), Ascaris lumbricoides (roundworm), Enterobius vermicularis (pinworm), Necator americanus (hookworm), and Trichuris trichiura (whipworm).

Initial Limit Quantity

Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength This drug is indicated for short-term acute use.

Drug	Limit
Albendazole	336 tablets / 365 days
Biltricide (praziquantel)	24 tablets / 365 days
Egaten (triclabendazole)	16 tablets / 365 days
Emverm (mebendazole)	12 tablets / 365 days

References

- 1. Albendazole [package insert]. Parsippany, NY: Edenbridge Pharmaceuticals, LLC; July.
- 2. Biltricide [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2023.
- 3. Egaten [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2022.
- 4. Emverm [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; August 2021.

Albendazole, Biltricide, Egaten, Emverm Limit 1583-H P03-2025.docx

© 2025 CVS Caremark. All rights reserved.

- 5. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. https://online.lexi.com. Accessed February 10, 2025.
- 6. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 02/10/2025).
- 7. Parasites Cysticercosis. Available at: https://www.cdc.gov/cysticercosis/hcp/clinical-care/. Accessed February 20, 2025.
- 8. Parasites Taeniasis. Available at: https://www.cdc.gov/taeniasis/hcp/clinical-care/index.html. Accessed February 20, 2025.
- 9. Parasites Diphyllobothrium. Available at: https://www.cdc.gov/diphyllobothrium/hcp/clinical-overview/. Accessed February 20, 2025.
- 10. Parasites Hymenolepiasis. Available at: https://www.cdc.gov/hymenolepis/hcp/clinical-care/. Accessed February 20, 2025.
- 11. Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015–2018. National Center for Health Statistics. Vital Health Stat 3(46). 2021. Available at: https://stacks.cdc.gov/view/cdc/100478. Accessed February 10, 2025.